Introduction
============

Infertility is defined as the inability of a couple to conceive spontaneously after at least 12 months of regular sexual intercourse without contraception. An estimated 15% of couples in developed countries are affected by infertility [@R8373246-1] . Despite major advances, clinical and laboratory-assisted reproductive techniques (ART) continue to yield low fertility success rates due to their dependence on multiple hormone and cytokine pathways [@R8373246-2] , [@R8373246-3] , [@R8373246-4] . For example, embryo implantation, a very critical process during ART, is regulated by various factors such as embryo quality, endometrial receptivity and embryo--endometrium synchronization.

Human chorionic gonadotropin (hCG), a unique heterodimeric placental glycoprotein hormone with biological functions in the endometrium and corpus luteum, is among the most important factors affecting implantation [@R8373246-5] ,  [@R8373246-6] . Before implantation, hCG directly promotes the expression of angiogenic factors such as vascular endothelial growth factor (VEGF) and stimulates the growth of maternal blood vessels by binding to endometrial receptors [@R8373246-7] . A recent animal model study indicated that the systemic administration of hCG at the time of embryo transfer (ET) improved the subsequent pregnancy rate [@R8373246-8] . Another study demonstrated that the intrauterine injection of hCG before ET improved the implantation and pregnancy rates during in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles [@R8373246-3] . Still, the reported effects of hCG intrauterine injection before embryo transfer during assisted reproduction have not been completely consistent [@R8373246-9] ,  [@R8373246-10] ,  [@R8373246-11] ,  [@R8373246-12] ,  [@R8373246-13] ,  [@R8373246-14] .

The most recent systematic review of the effects of intrauterine HCG injection on IVF outcomes was published in 2016 [@R8373246-15] . The authors of that review identified eight relevant studies and demonstrated that patients in the intrauterine hCG injection group had a significantly higher clinical pregnancy rate when compared with the control group (risk ratio \[RR\] = 1.18, 95% confidence interval \[CI\]: 1.00 -- 1.39, i.e., no difference from a 1.39-fold increased effect). However, the authors included two oral abstracts in their analysis of the clinical pregnancy rate and therefore did not provide a reliable meta-analysis of this topic. The present meta-analysis therefore aimed to search the literature and identify the results of randomized controlled trials (RCTs) that compared the IVF/ISCI outcomes of subjects who received intrauterine hCG injection before embryo transfer with those of controls.

Materials and Methods
=====================

Literature search strategy
--------------------------

Two authors (THP and HSF) independently and systematically searched the electronic databases PUBMED, EMBASE and Web of Science for published studies from inception to June 2018. The following core search terms were used: "hCG", "rhCG", "recombinant hCG", "human chorionic gonadotrophin", "assisted reproductive techniques", "IVF", "in vitro fertilization", "ICSI", "intracytoplasmic sperm injections", "embryo transfer", "intrauterine injection", "intrauterine HCG", "implantation", "RCT" and "randomized controlled trial". The search was limited to articles published in English. The reference lists from the identified articles were also screened manually.

Inclusion and exclusion criteria
--------------------------------

Studies that met the following criteria were included:

1.  a RCT design;

2.  an intervention involving intrauterine hCG injection vs. no injection or placebo;

3.  inclusion of sub-fertile women undergoing IVF/ICSI;

4.  inclusion of sub-fertile women undergoing embryo transfer and

5.  at least 1 of the following outcomes: implantation rate, clinical pregnancy rate, abortion rate, ongoing pregnancy rate and ectopic pregnancy rate.

The following exclusion criteria were also applied:

1.  studies without original data, such as case reports, abstracts, reviews and letters;

2.  studies without a RCT design, such as cohort studies, case-control studies and retrospective studies;

3.  an inability to extract data from the literature and

4.  animal experiments.

Data extraction and quality assessment
--------------------------------------

Two investigators (YQ and CY) independently extracted the following outcome-related data from the eligible studies: first authorʼs name, year of publication, country, study size and main results. Additionally, two authors (THP and WCL) assessed the quality of each study using the Cochrane Collaboration tool [@R8373246-16] , which screened the studies for the following methodological features: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias. Disagreements and uncertainty were resolved by discussion with a third author (JL) until consensus was achieved.

Statistical analysis
--------------------

Statistical analyses were conducted using Review Manager 5.2 (Cochrane Collaboration). Heterogeneity across studies was assessed using I ^2^ values and standard χ ^2^ tests. An I ^2^  ≥ 50% indicated significant heterogeneity, and a random-effects model was applied for the subsequent meta-analysis. Otherwise, a fixed-effects model was applied. Data are presented as risk ratios (RRs) with 95% confidence intervals (CIs). Publication bias was evaluated using a funnel plot.

Results
=======

Study selection and quality assessment
--------------------------------------

The details of the literature search strategy are presented in [Fig. 1](#FI8373246-1){ref-type="fig"} . The search strategy initially identified 658 articles. After screening the titles and abstracts and applying the inclusion/exclusion criteria, 636 articles were excluded. Of the 22 articles that met the initial selection criteria, 10 were excluded after a careful reading of the full text. Finally, this meta-analysis included 12 RCTs [@R8373246-3] ,  [@R8373246-9] ,  [@R8373246-10] ,  [@R8373246-11] ,  [@R8373246-12] ,  [@R8373246-13] ,  [@R8373246-14] ,  [@R8373246-17] ,  [@R8373246-18] ,  [@R8373246-19] ,  [@R8373246-20] ,  [@R8373246-21] involving 3241 patients. The characteristics of each included study are listed in [Table 1](#TB8373246-1){ref-type="table"} . The review authorsʼ judgments regarding each risk-of-bias item for each study are presented in [Table 2](#TB8373246-2){ref-type="table"} .

![ Flow diagram of the study selection process for the meta-analysis.](10-1055-a-0837-3246-igf01){#FI8373246-1}

###### 

**Table 1**  Characteristics of the studies included in the meta-analysis.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)       Country   Embryo stage                     Country   Patients (n)                         Outcomes included in the meta-analysis   
  ------------------- --------- -------------------------------- --------- ------------------------------------ ---------------------------------------- -----------------------------------------------------------------------------------------------------------
  Mansour (2011)      Egypt     Cleavage                         Egypt     500 IU: 107                          105/93                                   Clinical pregnancy rate

  Hong (2014)         USA       Blastocyst fresh or frozen       USA       500 IU: 148                          152                                      Implantation rate, clinical pregnancy rate, ongoing pregnancy rate, abortion rate

  Santibañez (2014)   Mexico    Day 3 fresh or frozen            Mexico    500 IU: 101                          109                                      Clinical pregnancy rate

  Zarei (2014)        Iran      Day 3                            Iran      250 µg (equivalent to 6500 IU): 84   98                                       Implantation rate, clinical pregnancy rate, abortion rate, ongoing pregnancy rate, ectopic pregnancy rate

  Aaleyasin (2015)    Iran      Day 2 -- 3                       Iran      500 IU: 240                          243                                      Clinical pregnancy rate, Implantation rate, abortion rate, live birth rate

  Wirleitner (2015)   Austria   Day 5 blastocyst                 Austria   500 IU: 599                          587                                      Implantation rate, clinical pregnancy rate, abortion rate, live birth rate

  Dehghani (2016)     Iran      Day 2 -- 3                       Iran      500 IU: 53\                          51                                       Clinical pregnancy rate, abortion rate
                                                                           1000 IU: 53                                                                   

  Hossini (2016)      Iran      Cleavage or blastocyst, frozen   Iran      500 IU: 50                           50                                       Implantation rate, clinical pregnancy rate, ongoing pregnancy rate

  Huang (2016)        China     Day 3 frozen                     China     1000 IU: 62                          50                                       Clinical pregnancy rate, abortion rate, ongoing pregnancy rate

  Navali (2016)       Iran      Day 3 fresh                      Iran      500 IU: 71                           67                                       Clinical pregnancy rate, ongoing pregnancy rate, abortion rate, ectopic pregnancy rate

  Mostajeran (2017)   Iran      Blastocyst                       Iran      700 IU: 46                           48                                       Clinical pregnancy rate

  Hafezi (2018)       India     Cleavage frozen                  India     500 IU: 60                           60                                       Clinical pregnancy live, abortion rate, live birth rate
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

**Table 2**  Quality assessment of the included studies.

  Author (year)                 Random Sequence Generation   Allocation Concealment   Blinding of participants and personnel   Blinding of outcome assessment   Incomplete outcome data   Selective reporting   Other bias
  ----------------------------- ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- --------------------- ------------
  Mansour (2011)                Yes                          Yes                      Unclear                                  Unclear                          No                        Unclear               Unclear
  Hong (2014)                   Yes                          Yes                      Yes                                      Yes                              Yes                       Yes                   Unclear
  Santibañez (2014)             Yes                          Unclear                  Yes                                      Yes                              Yes                       Unclear               Unclear
  Zarei (2014)                  Yes                          Unclear                  Yes                                      Yes                              No                        Unclear               Unclear
  Aaleyasin (2015)              Yes                          No                       No                                       No                               Yes                       Yes                   Yes
  Wirleitner (2015)             Yes                          Unclear                  Yes                                      Yes                              Yes                       Unclear               Yes
  Dehghani Firouzabadi (2016)   Yes                          Yes                      Unclear                                  Unclear                          Yes                       Unclear               Unclear
  Hossini (2016)                Yes                          Yes                      Yes                                      Yes                              Yes                       Unclear               Unclear
  Huang (2016)                  Yes                          Unclear                  Yes                                      Unclear                          Yes                       Unclear               Unclear
  Navali (2016)                 Yes                          Yes                      Yes                                      Yes                              Yes                       Unclear               Unclear
  Mostajeran (2017)             Yes                          Unclear                  Yes                                      Unclear                          Yes                       Unclear               Unclear
  Hafezi (2018)                 Yes                          Unclear                  Yes                                      Unclear                          No                        Unclear               Unclear

Implantation rate
-----------------

Only four studies [@R8373246-14] ,  [@R8373246-17] ,  [@R8373246-18] ,  [@R8373246-20] evaluated the implantation rate. As significant heterogeneity was observed among the included studies (I ^2^  = 92%, p \< 0.00001), a random effect model was applied. Here, a meta-analysis found no evidence of a difference in implantation rates between the hCG and control groups (RR = 1.30; 95% CI: 0.89 -- 1.90) ( [Fig. 2 a](#FI8373246-2){ref-type="fig"} ).

![ Forest plots of randomized controlled trials (RCTs) comparing patients who received intrauterine hCG administration vs. no hCG. **a**  Implantation rate; **b**  clinical pregnancy rate. CI = confidence interval.](10-1055-a-0837-3246-igf02ab){#FI8373246-2}

Next, a subgroup analysis was performed to determine whether the hCG dose (500 vs. \> 500 IU) or ET stage (cleavage vs. blastocyst) would affect the implantation rate. Although we observed no significant difference in the implantation rates when the subgroup receiving 500 IU intrauterine hCG was compared with the control group (RR = 1.23; 95% CI: 0.80 -- 1.88; 3 studies), evidence indicated a significantly increase in the implantation rate among subjects who received \> 500 IU intrauterine hCG (RR = 1.64; 95% CI: 1.04 -- 2.61; 1 study). Furthermore, the subgroup of women who received cleavage-stage ETs with intra-cavity hCG (IC-hCG) exhibited a greater increase in the implantation rate, compared to those who received cleavage-stage ETs without IC-hCG (RR = 1.88; 95% CI: 1.52 -- 2.32; two studies). However, a data synthesis revealed no significant difference in the implantation rates of women who received blastocyst-stage ETs with IC-hCG, compared to those who received blastocyst-stage ETs without IC-hCG (RR = 0.97; 95% CI: 0.81 -- 1.17; two studies) ( [Table 3](#TB8373246-3){ref-type="table"} ).

###### 

**Table 3**  Effect of ET stage (cleavage vs. blastocyst stage) on the results of the meta-analysis.

  Subgroup title                          No. of studies   No. of participants   Effect size (RR)      p-value
  --------------------------------------- ---------------- --------------------- --------------------- -------------
  Implantation rate                       4                3242                  1.30 \[0.89, 1.90\]   \< 0.00001
  HCG cleavage vs. control cleavage       2                1582                  1.88 \[1.52, 2.32\]   0.53
  HCG blastocyst vs. control blastocyst   2                1659                  0.97 \[0.81, 1.17\]   0.1
  Clinical pregnancy rate                 11               3245                  1.30 \[1.09, 1.55\]   0.14
  HCG cleavage vs. control cleavage       8                1665                  1.38 \[1.16, 1.65\]   0.52
  HCG blastocyst vs. control blastocyst   3                1580                  1.11 \[0.83, 1.48\]   0.09
  Abortion rate                           9                2729                  1.06 \[0.78, 1.44\]   0.69
  HCG cleavage vs. control cleavage       7                1243                  1.16 \[0.73, 1.86\]   0.79
  HCG blastocyst vs. control blastocyst   2                1486                  0.99 \[0.66, 1.49\]   0.98
  Ongoing pregnancy rate                  4                915                   1.81 \[1.48, 2.21\]   \< 0.00 001
  HCG cleavage vs. control cleavage       4                915                   1.81 \[1.48, 2.21\]   \< 0.00 001
  Live birth rate                         3                1789                  0.99 \[0.60, 1.63\]   \< 0.00 001
  HCG cleavage vs. control cleavage       2                603                   0.99 \[0.34, 2.86\]   0.0005
  HCG blastocyst vs. control blastocyst   1                1186                  0.93 \[0.80, 1.07\]   0.29

Clinical pregnancy rate
-----------------------

As shown in [Fig. 2 b](#FI8373246-2){ref-type="fig"} , all included studies [@R8373246-3] ,  [@R8373246-9]  --  [@R8373246-14] ,  [@R8373246-17] ,  [@R8373246-18] ,  [@R8373246-19] ,  [@R8373246-20] ,  [@R8373246-21] reported the clinical pregnancy rate, and significant heterogeneity was observed among the studies (I ^2^  = 73%, p \< 0.0001). A random effects model analysis of the pooled data revealed a statistically significant increase in the clinical pregnancy rate in the hCG group, compared with the control group (RR = 1.33; 95% CI: 1.12 -- 1.58).

A subgroup analysis was conducted to determine whether the hCG dose (500 vs. \> 500 IU) or ET stage (cleavage vs. blastocyst) would affect the clinical pregnancy rate. Notably, the RRs for the subgroups receiving 500 and \> 500 IU hCG were 1.26 (95% CI: 1.04 -- 1.53; 9 studies) and 1.60 (95% CI: 1.19 -- 2.16; 4 studies), respectively, relative to the controls. Furthermore, among women receiving cleavage-stage ETs, the clinical pregnancy rate was higher for those with IC-hCG, compared to those without IC-hCG (RR = 1.30; 95% CI: 1.09 -- 1.55; eight studies). However, the data synthesis of women receiving blastocyst-stage ETs revealed no significant difference in the clinical pregnancy rate between those with and without IC-hCG (RR = 1.11; 95% CI: 0.83 -- 1.48; three studies) ( [Table 3](#TB8373246-3){ref-type="table"} ).

Abortion rate
-------------

Eight included studies [@R8373246-10] ,  [@R8373246-11] ,  [@R8373246-13] ,  [@R8373246-14] ,  [@R8373246-17] ,  [@R8373246-18] ,  [@R8373246-20] ,  [@R8373246-21] reported the abortion rate, and no heterogeneity was observed among these studies (I ^2^  = 0%, p = 0.68). A meta-analysis identified no statistically significant difference in the abortion rates of the ICG and control groups (fixed-effect model; RR = 1.06; 95% CI: 0.78 -- 1.44) ( [Fig. 3 a](#FI8373246-3){ref-type="fig"} ).

![](10-1055-a-0837-3246-igf03ab){#FI8373246-3}

![ Forest plots of randomized controlled trials (RCTs) comparing patients who received intrauterine hCG administration vs. no hCG. **a**  Abortion rate; **b**  ongoing pregnancy rate; **c**  ectopic pregnancy rate; **d**  live birth rate. CI = confidence interval.](10-1055-a-0837-3246-igf03cd){#FI8373246-3cd}

A subgroup analysis was conducted to determine whether the hCG dose (500 vs. \> 500 IU) or ET stage (cleavage vs. blastocyst) would affect the abortion rate. Compared to the control group, women who received 500 and \> 500 IU hCG had RRs of 1.07 (95% CI: 0.77 -- 1.47; six studies) and 1.04 (95% CI: 0.41 -- 2.65; three studies), respectively. Furthermore, a data synthesis revealed no significant differences in the abortion rates between women with and without IC-hCG in both the subgroups receiving cleavage-stage and blastocyst-stage ETs (RR = 1.16; 95% CI: 0.73 -- 1.86 and RR = 0.99; 95% CI: 0.66 -- 1.49; respectively) ( [Table 3](#TB8373246-3){ref-type="table"} ).

Ongoing pregnancy rate
----------------------

As shown in [Fig. 3 b](#FI8373246-3){ref-type="fig"} , five of the included studies [@R8373246-11] ,  [@R8373246-12] ,  [@R8373246-17] ,  [@R8373246-18] ,  [@R8373246-21] reported the ongoing pregnancy rate, and a low level of heterogeneity was detected among these studies (I ^2^  = 18%, p = 0.30). A fixed effects model analysis of the pooled data revealed a significantly higher ongoing pregnancy rate in the hCG group, compared with the control group (RR = 1.87; 95% CI: 1.54 -- 2.27).

Next, a subgroup analysis was conducted to determine whether the hCG dose (500 vs. \> 500 IU) or ET stage (cleavage vs. blastocyst) would affect the ongoing pregnancy rate. Compared to the control group, the RRs for women receiving 500 and \> 500 IU hCG were 1.87 (95% CI: 1.49 -- 2.36; three studies) and 1.86 (95% CI: 1.28 -- 2.69; two studies), respectively. Additionally, among women receiving cleavage-stage ETs, those with IC-hCG had a higher ongoing pregnancy rate, compared to those without IC-hCG (RR = 1.8; 95% CI: 1.48 -- 2.21; 4 studies) ( [Table 3](#TB8373246-3){ref-type="table"} ).

Ectopic pregnancy rate
----------------------

As shown in [Fig. 3 c](#FI8373246-3){ref-type="fig"} , three studies [@R8373246-10] ,  [@R8373246-18] ,  [@R8373246-21] reported the ectopic pregnancy rate, and no heterogeneity was detected (I ^2^  = 0%, p = 0.47). The fixed effects model analysis of pooled data showed no evidence of a significant difference in the ectopic pregnancy rate between the ICG and control groups (RR = 0.77; 95% CI: 0.17 -- 3.42).

Live birth rate
---------------

As shown in [Fig. 3 d](#FI8373246-3){ref-type="fig"} , three studies [@R8373246-10] ,  [@R8373246-14] ,  [@R8373246-17] reported the live birth rate, and significant heterogeneity was observed (I ^2^  = 89%, p \< 0.0001). A random effects model analysis of the pooled data found no significant difference in the live birth rate between the ICG and control groups (RR = 0.99; 95% CI: 0.60 -- 1.63).

Next, a subgroup analysis was conducted to determine whether the ET stage (cleavage vs. blastocyst) would affect the live birth rate. However, the data synthesis revealed no significant difference in the live birth rate between women with and without IC-hCG in both the subgroups receiving cleavage-stage or blastocyst-stage ETs (RR = 0.99; 95% CI: 0.34 -- 2.86; two studies and RR = 0.93; 95% CI: 0.80 -- 1.07; respectively) ( [Table 3](#TB8373246-3){ref-type="table"} ).

Publication bias
----------------

A funnel plot was used to qualitatively evaluate publication bias among the studies comparing the clinical pregnancy rates of the hCG (≥ 500 IU) and control groups. The partially symmetrical funnel plot presented in [Fig. 4](#FI8373246-4){ref-type="fig"} indicates no potential publication bias in the included studies.

![ Funnel plot used to detect publication bias. RR = risk ratio.](10-1055-a-0837-3246-igf04){#FI8373246-4}

Discussion
==========

HCG rescues the maternal corpus luteum in early pregnancy via a classical endocrine mechanism [@R8373246-22] , and several studies have identified this hormone as a key factor during preparation for implantation and regulation of the uterine environment [@R8373246-23] ,  [@R8373246-24] ,  [@R8373246-25] ,  [@R8373246-26] . Recently, Ye et al. [@R8373246-27] reviewed pooled data from women who received intrauterine hCG injections at a very wide range of doses but did not evaluate publication bias in that meta-analysis. Ye and colleagues reported that intrauterine hCG injection significantly increased the rates of biochemical, clinical and ongoing pregnancy, compared with the control [@R8373246-27] . However, another meta-analysis [@R8373246-15] reported that intrauterine hCG administration had an ambiguous effect on the clinical pregnancy rate. However, that analysis included two oral abstracts, and the 95% CI of the applied RR included the value of 1 (i.e., no evidence of an effect).

In this meta-analysis, we specifically evaluated the effects of different intrauterine hCG doses prior to ET on various outcomes of ART. Our findings are important because this was the first study to separately analyze the effects of different doses of hCG (500 vs. \> 500 IU). Furthermore, our analysis retrieved six additional relevant studies published during the 2 years since the last meta-analysis [@R8373246-15] . Our results regarding the clinical and ongoing pregnancy rates, as well as the implantation rate, were consistent with the previous meta-analysis [@R8373246-15] and partially consistent with the previous by Ye and colleagues [@R8373246-27] . Furthermore, our analysis of the effects of embryonic stage on the outcomes revealed that women who received cleavage-stage ETs with IC-hCG exhibited increases in the implantation, clinical pregnancy and ongoing pregnancy rates, compared to their counterparts without IC-hCG.

HCG is secreted by the embryo during early development, and the level of this hormone in the culture media correlates positively with the grade of the developing embryo, as well as with the number of blastomeres [@R8373246-28] . Furthermore, hCG plays well-established and important roles in promoting angiogenesis and regulating the inflammatory response during embryo implantation. Therefore, the intrauterine administration of HCG before an ET can overcome decreases in endometrial receptivity induced by ART treatments [@R8373246-29] ,  [@R8373246-30] ,  [@R8373246-31] . Therefore, the intrauterine injection of hCG appears to increase the chance of implantation and to significantly increase the clinical and ongoing pregnancy rates.

This study had several strengths worth noting. First, this meta-analysis was based on rigorous methodology because all identified studies were RCTs. Second, the studies included in this meta-analysis were of a relatively satisfactory level of quality and fulfilled our predefined inclusion criteria. Third, a large number of individuals were pooled from various trials, which significantly enhanced the statistical power of the meta-analysis. Fourth, no obvious publication bias was identified, indicating that the results of this meta-analysis are unbiased.

Despite these important findings, however, our study also had some potential limitations. First, our analysis included only 12 RCTs, some of which included rather small numbers of participants. These factors might have affected the validity and reliability of the conclusions. Second, studies were retrieved only from online and English-language databases. Accordingly, several relevant studies may have been missed, and language bias may have been introduced. Third, although all included studies were RCTs, some did not report specific methods of randomization, such as allocation concealment and blinding, which may have led to publication and reporting biases. Fourth, the type of hCG was not consistent across studies, which might have affected the results of the meta-analysis. Finally, obvious heterogeneity was detected for several outcomes. This heterogeneity may be attributable to inter-study variations such as differences in inclusion and exclusion criteria, sample sizes and patient demographics (e.g., race, age, body mass index).

Conclusion
==========

Our results indicate that the intrauterine injection of hCG before ET led to improved clinical pregnancy and ongoing pregnancy rates. However, well-designed, large multi-center RCTs are warranted to provide further evidence.
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